 
        
        
        
                货号:A136104
                
                同义名:
                    
                        
                            
                                FTI-277 hydrochloride
                            
                        
                    
                
                
                
                    
                     
                    
                     
                
            
FTI-277 HCl是一种法尼基转移酶 (FTase) 抑制剂和高效的 Ras CAAX 肽模拟剂,能拮抗 H- 和 K-Ras 致癌信号通路。
 HazMat Fee +
 HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) | 
| Excepted Quantity | USD 0.00 | 
| Limited Quantity | USD 15-60 | 
| Inaccessible (Haz class 6.1), Domestic | USD 80+ | 
| Inaccessible (Haz class 6.1), International | USD 150+ | 
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ | 
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ | 
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI-0206965 | +++ ULK1, IC50: 108 nM ULK2, IC50: 711 nM | 95% | |||||||||||||||||
| Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
| Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
| PFK-015 | ++ PFKFB3, IC50: 207 nM | 99%+ | |||||||||||||||||
| MRT68921 HCl | ++++ ULK1, IC50: 2.9 nM ULK2, IC50: 1.1 nM | 99%+ | |||||||||||||||||
| ROC-325 | ✔ | 99%+ | |||||||||||||||||
| Autophinib | +++ Autophagy, IC50: 40 nM | 99% | |||||||||||||||||
| Lys05 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | Transferase ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tipifarnib | +++ FTase, IC50: 0.6 nM | 99%+ | |||||||||||||||||
| Tolcapone | + COMT, Ki: 30 nM | 99%+ | |||||||||||||||||
| Lonafarnib | +++ H-ras, IC50: 1.9 nM K-ras-4B, IC50: 2.8 nM | 99%+ | |||||||||||||||||
| (E)-Daporinad | ++++ NMPRTase, Ki: 0.4 nM | 99%+ | |||||||||||||||||
| FTI-277 HCl | ++++ FTase, IC50: 500 pM | 98% | |||||||||||||||||
| A 922500 | ++ human DGAT-1, IC50: 7 nM mouse DGAT-1, IC50: 24 nM | 98% | |||||||||||||||||
| Lomeguatrib | ++ O6-alkylguanine-DNA-alkyltransferas, IC50: 5 nM | 99%+ | |||||||||||||||||
| PF-04620110 | + DGAT1, IC50: 19 nM | 99% | |||||||||||||||||
| LB42708 | +++ FTase (K-Ras), IC50: 0.8 nM FTase (N-ras), IC50: 1.2 nM | 98% | |||||||||||||||||
| GGTI298 Trifluoroacetate | ✔ | 98%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | FTI-277, when used at 20 micrometers for 48 hours before irradiation, notably decreases the survival of radioresistant HeLa 3A cells expressing a 24-kDa isoform but does not affect the survival of control HeLa PINA cells. This radiosensitizing effect of FTI-277 is accompanied by an increase in postmitotic cell death in HeLa 3A cells and a decrease in G(2)/M phase arrest in both cell lines[1]. GGTI-298 and FTI-277 treatments hinder migration and invasion of PC-3 cells in both time- and dose-dependent manners[3]. | 
| 体内研究 | FTI-277 therapy prevents the rise in PTP-1B and PTEN protein levels seen in burned mice when compared to the vehicle control. Conversely, FTI-277 doesn't significantly change the expression levels of PTP-1B and PTEN in sham-burned mice[2]. | 
| 体外研究 | FTI-277, when used at 20 micrometers for 48 hours before irradiation, notably decreases the survival of radioresistant HeLa 3A cells expressing a 24-kDa isoform but does not affect the survival of control HeLa PINA cells. This radiosensitizing effect of FTI-277 is accompanied by an increase in postmitotic cell death in HeLa 3A cells and a decrease in G(2)/M phase arrest in both cell lines[1]. GGTI-298 and FTI-277 treatments hinder migration and invasion of PC-3 cells in both time- and dose-dependent manners[3]. | 
| Concentration | Treated Time | Description | References | |
| Human mesenchymal stem cells (MSC) | 5 µM and 10 µM | 1 week and 3 weeks | FTI-277 significantly affected osteoblast differentiation (approx. -50±10%) and function (approx. -60±15%), with a higher inhibitory effect at 10 μM. Alendronate reversed the inhibitory effect of FTI-277. | Br J Pharmacol. 2011 Mar;162(5):1109-18. | 
| Human mesenchymal stem cells (MSC) | 5 µM and 10 µM | 2 weeks | Assessed the effect of FTI-277 on HDJ-2 and prelamin A, finding that FTI-277 inhibited farnesylation of both proteins, with a dose-dependent increase in unfarnesylated protein levels. | Br J Pharmacol. 2011 Mar;162(5):1109-18. | 
| HELN cells | 10 µM | 24 hours | In HELN cells, FTI-277 and GGTI-298 stimulated basal transcriptional activity by 3.6-fold and 2.4-fold, respectively, in the absence of E2. In the presence of E2, FTI-277 and GGTI-298 further enhanced transcriptional activity by an additional 2.2-fold and 1.6-fold, respectively. | Breast Cancer Res. 2005;7(1):R60-70. | 
| MCF-7 cells | 10 µM | 24 hours | FTI-277 significantly enhanced E2-induced transcriptional activity. In the absence of E2, FTI-277 and GGTI-298 stimulated basal transcriptional activity by 8.4-fold and 3.9-fold, respectively. In the presence of E2, FTI-277 and GGTI-298 further enhanced transcriptional activity by an additional 4.1-fold and 2.5-fold, respectively. | Breast Cancer Res. 2005;7(1):R60-70. | 
| ESC-derived VEGFR2+ cells | 3 µM | 4 days | Under low-density culture conditions, FTI-277 significantly reduced PECAM1+ colony numbers and increased αSMA+ colonies, indicating specific inhibition of endothelial differentiation. | J Cell Biol. 2008 Apr 7;181(1):131-41. | 
| MCF7 breast cancer cells | 5 µM | 48 hours | Combined use of FTI-277 and IPA3 did not significantly inhibit cell proliferation | Mol Cancer. 2013 Aug 6;12(1):88. | 
| A549 lung cancer cells | 5 µM | 48 hours | Combined use of FTI-277 and IPA3 significantly inhibited cell proliferation | Mol Cancer. 2013 Aug 6;12(1):88. | 
| HT29 colon cancer cells | 5 µM | 48 hours | Combined use of FTI-277 and IPA3 significantly inhibited cell proliferation | Mol Cancer. 2013 Aug 6;12(1):88. | 
| A375MM melanoma cells | 5 µM or 15 µM | 48 hours | FTI-277 treatment did not affect PAK protein levels but increased nuclear PhoPAK clusters | Mol Cancer. 2013 Aug 6;12(1):88. | 
| HeLa cells | 5 µM or 15 µM | 48 hours | After 48 h of FTI-277 treatment, PAK and PhoPAK signals significantly increased | Mol Cancer. 2013 Aug 6;12(1):88. | 
| SH-SY5Y cells | 100 nM | 48 hours | Reduced the abundance of membrane-associated UCH-L1 (UCH-L1M), decreased α-synuclein levels, and increased cell viability | Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4635-40. | 
| MCF-7 cells | 10 µM | 48 hours | To evaluate the effect of FTI-277 on cell proliferation, results showed that FTI-277 treatment significantly inhibited the proliferation of MCF-7 cells. | Cancer Lett. 2010 Jan 28;287(2):172-81. | 
| 4T1 cells | 10 µM | 48 hours | To evaluate the effect of FTI-277 on cell proliferation, results showed that FTI-277 treatment significantly inhibited the proliferation of 4T1 cells. | Cancer Lett. 2010 Jan 28;287(2):172-81. | 
| 67NR cells | 10 µM | 48 hours | To evaluate the effect of FTI-277 on cell proliferation, results showed that FTI-277 treatment significantly inhibited the proliferation of 67NR cells. | Cancer Lett. 2010 Jan 28;287(2):172-81. | 
| ESC-derived VEGFR2+ cells | 1 µM | 48 hours | FTI-277 added within 3 hours post-VEGF-A stimulation suppressed endothelial differentiation, but no effect when added after 6 hours, demonstrating time-dependent inhibition. | J Cell Biol. 2008 Apr 7;181(1):131-41. | 
| COS-7 cells | 100 nM | Decreased the amount of transfected WT UCH-L1M | Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4635-40. | |
| B16F10 melanoma cells | 10 or 20 µM | 48 hours | FTI-277 did not enhance membrane FasL expression | Neoplasia. 2007 Dec;9(12):1078-90. | 
| Human bronchial mesenchymal fibroblasts | 10 µM | 48 hours | To investigate the effect of FTI-277 on TGFβ1-induced fibronectin expression; results showed no significant inhibition of fibronectin accumulation | Respir Res. 2011 Aug 24;12(1):113. | 
| MCF-7 cells | 5.9 nM | 5 days | To evaluate the inhibitory effects of FTI-277 in combination with different anti-estrogens on MCF-7 cell proliferation. Results showed that FTI-277 combined with Tam had an additive effect, while combinations with ICI182,780 or PBPE exhibited synergistic effects. | Breast Cancer Res. 2005;7(6):R1159-67. | 
| CNE1 cells | 1 µM | 72 hours | FTI-277 in combination with cisplatin slightly enhanced cytotoxicity in NPC cells with medium CENP-F expression | Mol Cancer. 2010 Sep 9;9:237. | 
| HONE1 cells | 1 µM | 72 hours | FTI-277 in combination with cisplatin significantly enhanced cytotoxicity in NPC cells with high CENP-F expression | Mol Cancer. 2010 Sep 9;9:237. | 
| Murine bone marrow-derived mast cells | 5 µM | 72 hours | Inhibition of Ras isoprenylation significantly reduces mast cell degranulation, cytokine production, and migration | 2020 Oct 28;11:585070. doi: 10.3389/fimmu.2020.585070. | 
| 3T3-L1 cells | 20 µM(first 24 h), then 2.5 µM (next 7 days) | 8 days | To investigate the effect of FTI-277 on adipogenesis in 3T3-L1 cells. Results showed that FTI-277 increased the number of mature adipocytes, but when combined with non-farnesylated prelamin A accumulation, it reduced the expression of adipogenic genes. | Int J Mol Sci. 2024 Jan 20;25(2):1282. | 
| CHO-K1 cells | 1 µM | 8 hours | An 8 h treatment with 1μM FTI-277 led to an increase in p27 expression in cells that were selected before analysis for H-2Kk expression on magnetic beads conjugated to a monoclonal antibody against H-2Kk. | EMBO Rep. 2004 Jul;5(7):721-7. | 
| HeLa cells | 1 µM | 8 hours | Addition of FTI-277 resulted in a 10- to 20-fold increase in LucF translation with a reporter containing the R17-binding site. | EMBO Rep. 2004 Jul;5(7):721-7. | 
| SK-Hep1 cells | 1 µM | 8 hours | FTI-277 prevents the membrane association of the CAAX motif and thus increases the cytoplasmic levels of the eIF4G fusion protein, which is then capable of inducing translation of the second cistron of a bicistronic messenger RNA containing an R17-binding site in its intercistronic space. | EMBO Rep. 2004 Jul;5(7):721-7. | 
| Administration | Dosage | Frequency | Description | References | ||
| Mice | E6.75 whole-embryo culture model | In vitro culture medium | 10 μM | Single dose, cultured for 3 days | FTI-277 treatment diminished PECAM1+ vessels in yolk sacs, with decreased PECAM1 and VE-cadherin mRNA levels but unchanged αSMA expression, suggesting suppression of vascular development. | J Cell Biol. 2008 Apr 7;181(1):131-41. | 
| Mice | Dopaminergic neurons in midbrain mixed primary cultures | Added to culture medium | 100 nM | Single treatment, duration not specified | Reduced α-synuclein toxicity | Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4635-40. | 
| Mice | HBV transgenic mice | Intraperitoneal injection | 50 mg/kg/day | Once daily for 7 days | FTI-277 and FTI-2153 were both highly effective at clearing HDV viremia | J Clin Invest. 2003 Aug;112(3):407-14 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.07mL 0.41mL 0.21mL | 10.33mL 2.07mL 1.03mL | 20.66mL 4.13mL 2.07mL | |
| CAS号 | 180977-34-8 | 
| 分子式 | C22H30ClN3O3S2 | 
| 分子量 | 484.07 | 
| SMILES Code | CSCC[C@@H](C(OC)=O)NC(C1=CC=C(NC[C@@H](N)CS)C=C1C2=CC=CC=C2)=O.[H]Cl | 
| MDL No. | MFCD28385886 | 
| 别名 | FTI-277 hydrochloride | 
| 运输 | 蓝冰 | 
| InChI Key | PIAFFJUUNXEDEW-PXPMWPIZSA-N | 
| Pubchem ID | 88309922 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, 2-8°C | 
| 溶解方案 | DMSO: 105 mg/mL(216.91 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 100 mg/mL(206.58 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1